Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease by Rachel Black | Jun 25, 2025 | Uncategorized
Cellarity Appoints Percy Carter, MBA, Ph.D., as Member of Board of Directors by Rachel Black | Jul 25, 2024 | Uncategorized
Cellarity Appoints Head of Platform to Advance Vision for Novel Drug Creation by Rachel Black | May 7, 2024 | Uncategorized
The Future of Biotech in an Artificially Intelligent World by Rachel Black | Jan 6, 2022 | Uncategorized
Recent Comments